Platelet-derived growth factor (PDGF) is a family of growth regulatory molecules that serves as key regulators of proliferation and migration in cells of mesenchymal origin, 1 including vascular smooth muscle cells (SMCs). These cells express and respond to PDGF via high-affinity cell surface receptors (␣ and ␤). 2 PDGFs play an important role in blood vessel development and in the pathogenesis of atherosclerosis and restenosis after balloon angioplasty. [1] [2] [3] [4] [5] In addition to the classic PDGFs (PDGF-A and PDGF-B), identified more than 2 decades ago, 2 novel PDGF chains (PDGF-C and PDGF-D) have recently been described. 6 The human PDGFD gene is located on chromosome 11q22.3 and spans 200 kb of gDNA. It encodes a polypeptide of 370 amino acid residues, which unlike PDGF-A and -B, appears to only homodimerize but not heterodimerize with other PDGF chains. PDGF-DD is secreted as a latent dimer that requires activation by proteolytic cleavage. 6-9 PDGF-D mRNA (4 kb) is widely expressed in organs such as the heart, pancreas, kidney, and ovary. 7, 10, 11 PDGF-D is also expressed in small and large vessel-derived endothelial cells in culture, 2 although its expression in intact vessels is not fully established. Recent studies have shown that PDGF-DD promotes tumor growth by accelerating tumor cell proliferation and stimulating tumor neovascularization. 10, 12, 13 Furthermore, PDGF-D was shown to increase macrophage recruitment, interstitial fluid pressure as well as the maturation of blood vessels during angiogenesis. 14 PDGF-D does not appear to be regulated by hypoxic conditions, or VEGF-C, fibroblast growth factor-1, or tumor necrosis factor-␣, at least in human endothelial cells. 2 The molecular mechanisms involved in the regulation of PDGF-D expression at the level of transcription, however, are yet to be elucidated.
Introduction
Platelet-derived growth factor (PDGF) is a family of growth regulatory molecules that serves as key regulators of proliferation and migration in cells of mesenchymal origin, 1 including vascular smooth muscle cells (SMCs). These cells express and respond to PDGF via high-affinity cell surface receptors (␣ and ␤). 2 PDGFs play an important role in blood vessel development and in the pathogenesis of atherosclerosis and restenosis after balloon angioplasty. [1] [2] [3] [4] [5] In addition to the classic PDGFs (PDGF-A and PDGF-B), identified more than 2 decades ago, 2 novel PDGF chains (PDGF-C and PDGF-D) have recently been described. 6 The human PDGFD gene is located on chromosome 11q22.3 and spans 200 kb of gDNA. It encodes a polypeptide of 370 amino acid residues, which unlike PDGF-A and -B, appears to only homodimerize but not heterodimerize with other PDGF chains. PDGF-DD is secreted as a latent dimer that requires activation by proteolytic cleavage. [6] [7] [8] [9] PDGF-D mRNA (4 kb) is widely expressed in organs such as the heart, pancreas, kidney, and ovary. 7, 10, 11 PDGF-D is also expressed in small and large vessel-derived endothelial cells in culture, 2 although its expression in intact vessels is not fully established. Recent studies have shown that PDGF-DD promotes tumor growth by accelerating tumor cell proliferation and stimulating tumor neovascularization. 10, 12, 13 Furthermore, PDGF-D was shown to increase macrophage recruitment, interstitial fluid pressure as well as the maturation of blood vessels during angiogenesis. 14 PDGF-D does not appear to be regulated by hypoxic conditions, or VEGF-C, fibroblast growth factor-1, or tumor necrosis factor-␣, at least in human endothelial cells. 2 The molecular mechanisms involved in the regulation of PDGF-D expression at the level of transcription, however, are yet to be elucidated.
Here we report the first isolation and functional characterization of the PDGF-D promoter. Basal and inducible PDGF-D transcription is regulated by the winged helix-turn-helix factor and prototypic Ets family member, Ets-1 15 in vascular SMCs via the Ϫ470 GGAT Ϫ467 motif in the PDGF-D promoter. This element (D3) also serves as a novel cis-acting element for the zinc finger transcription factor Sp1. 16 H 2 O 2 activates PDGF-D transcription at nanomolar concentrations in SMCs in a manner critically dependent on D3 and the presence of both Ets-1 and Sp1. We also demonstrate here that angiotensin II (ATII)-inducible Ets-1 and PDGF-D expression is mediated via the endogenous generation of H 2 O 2 .
Materials and methods

Plasmid constructs
To generate the p1168PDGF-Dluc construct, about 1.3 kb of fragment containing the promoter region of the PDGFD gene was amplified by polymerase chain reaction (PCR) with human gDNA and the according primers (upstream: 5Ј-GAG CTA GCG AGA ATC CCA AAA GCC TCA A-3Ј; downstream: 5Ј-CTC TCG AGG CGG GGT TGC AGA AGT GT-3Ј, which contain NheI and XhoI restriction enzyme sites [underlined] ). The amplified fragment was cloned into the luciferase reporter vector pGL3-basic (Promega, Madison, WI) between the NheI and XhoI restriction sites. Mutagenesis of the Ets-1-binding site on Ϫ1168/ϩ185PDGF-D promoter was performed using the Quick Change site-directed mutagenesis kit (Stratagene, LaJolla, CA).
Cell culture
Primary rat aortic SMCs and bovine aortic endothelial cells were obtained from Cell Applications (San Diego, CA) and cultured in Waymouth and DMEM (Invitrogen, Carlsbad, CA), respectively, containing 10% fetal bovine serum, 10 U/mL penicillin, and 10 g/mL streptomycin at 37°C in a humidified atmosphere of 5% CO 2 /air. Cells were passaged every 3 to 4 days in 75-cm 2 flasks by first rinsing twice with PBS (pH 7.4), and then incubating with 0.05% trypsin, 0.02% EDTA in HBSS (BioWhittaker, Walkersville, MD) for 3 minutes at 37°C prior to resuspending in growth medium. Cells were not used in experiments beyond passage 8.
Primer extension
Primer extension was performed using the Primer Extension System-AMV Reverse Transcriptase according to manufacturer's (Promega) protocol. Total RNA from human primary SMCs was extracted using TRIzol reagent. Total RNA (5 g) was used in the primer extension reaction. The 2 sets of PDGF-D primers used in the experiments are located 5Ј to the translational start site ATG of human PDGF-D; primer A: 5Ј-TCG CTG TGC TAA TCG CCG AGC TCT C-3Ј, primer B: 5ЈCGC CGC CCT GCG CTC TCG CCG CCT G-3Ј.
Transient transfection and luciferase assays
SMCs in 100-mm culture dishes at 60% to 70% confluence were transfected with 10 g PDGF-D promoter reporter vector together with the indicated amount of Ets-1 or Sp1 expression vectors using FuGENE6 (Roche Molecular Biochemicals, Indianapolis, IN). For agonist studies, SMCs were incubated in serum-free media for 6 hours before transfection of plasmids and treatment with H 2 O 2 . Luciferase activity was quantified 24 hours after transfection using the dual luciferase assay system (Promega).
Preparation of nuclear extracts
SMCs were washed twice with cold PBS and scraped off the plates. The cells were centrifuged at 340 g for 15 minutes at 4°C; the pellets were resuspended in cold PBS and transferred to Eppendorf tubes. The cell suspension was repelleted using a microfuge at 4000 g for 60 seconds at 4°C. The cells were lysed by incubation in buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5% Nonidet P-40, 1 mM dithiothreitol [DTT], 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 10 mg/mL leupeptin, 4 mg/mL aprotinin) for 5 minutes on ice. The suspension was recentrifuged at full speed for 40 seconds, and the pellet was resuspended with buffer C (20 mM HEPES, pH 8, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10 mg/mL leupeptin, 4 mg/mL aprotinin). After a spin at full speed, an equal volume of buffer D (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.5 mM PMSF, 10 mg/mL leupeptin, 4 mg/mL aprotinin) was added to the supernatant. Extracts were immediately frozen on dry ice and stored at Ϫ80°C until use.
Electrophoretic mobility shift assay
SMC nuclear extracts or recombinant Ets-1, Sp1 protein were incubated with the indicated 32 P-labeled double-stranded oligonucleotides for 20 minutes on ice. Where indicated, nuclear extracts were incubated with unlabeled double-stranded oligonucleotide or antibody for 10 minutes prior to the addition of the probe. The Ets-1 antibody did not bind Sp1 in isolation, nor did the Sp1 antibody bind to Ets-1 in isolation. The samples were resolved by 6% non-denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. 
Extraction of total RNA and RT-PCR
Cell extraction and Western blot analysis
SMCs (60%-70% confluent) in 100-mm Petri dishes were arrested for 24 hours in serum-free medium before being treated with agonist. SMCs were washed twice with cold PBS, scraped, and suspended in RIPA buffer containing protease inhibitors (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% deoxycholate, 0.1% Triton X-100, 5 mg/mL leupeptin, 100 mM PMSF, 10% Trasylol, 0.5 M EDTA). The suspension was spun at maximum speed at 4°C for 10 minutes, the supernatant was collected, and protein concentration was assayed by BCA protein assay kit (Pierce, Rockford, IL). Cell lysates (15 g) were resolved in 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto Immobilon PVDF transfer membranes (Millipore, New Bedford, MA). Membranes were blocked overnight at 4°C with 5% skim milk in 0.05% Tween-20/PBS, then incubated with the appropriate primary antibody (PDGF-D and Ets-1 at 1:300-1000 dilution) for 1 hour at room temperature. Swine anti-rabbit or rabbit anti-goat IgG conjugated with horseradish peroxidase (HRP) was then incubated for 1 hour. In peptide blockade experiments, the primary PDGF-D antibody (1:300, 0.6 g/mL final concentration) was incubated alone or in combination with blocking PDGF-D peptide (sc-23573P; 3.3 g/mL final concentration) for 1 hour at 37°C prior to incubation with the filters, in accordance with the manufacturer's instructions (Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were incubated with chemiluminescence (Perkin Elmer Life Sciences, Shelton, CT) then exposed to film for 1 to 10 minutes.
Real-time quantitative PCR
Total RNA was prepared using TRIzol reagent, and 2 g was used for synthesis of cDNA in 20 L in the presence of 0. For personal use only. on July 8, 2017 . by guest www.bloodjournal.org From rat GAPDH: (forward) 5Ј-ACA AGA TGG TGA AGG TCG GTG-3Ј, (reverse) 5Ј-AGA AGG CAG CCC TGG TAA CC-3Ј. The PCR conditions were: 50°C for 2 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Product sizes were: PDGF-D (129 bp) and GAPDH (69 bp). 
ChIP analysis
Human SMCs grown in 100-mm Petri dishes (ϳ80%-90% confluent) were washed with PBS, pH 7.4, before chromatin immunoprecipitation 17 (ChIP) using the appropriate antibody. PCR was performed in 1 mM MgCl 2 , 0.1 mM dNTP, 0.1 M primers, and 1 U platinum Taq polymerase (Invitrogen). Amplification conditions were as follows: 94°C for 2 minutes; 40 cycles of 94°C for 30 seconds, 54°C for 10 seconds, and 72°C for 30 seconds; with another extension time of 4 minutes. PDGF-D promoter containing the Ets-1-and Sp1-binding sites was amplified using 2 sets of primers: ChipPDGFDF1 primer 5Ј-TGATAGATGGAGGGACTCAAG-3Ј and ChipPDGFDR1 primer 5Ј-CAGGAAACAAACTCGCCAG-3Ј; ChipPDG-FDF2 primer 5Ј-CATCAGTCTCGACCTTTTCTC-3Ј and ChipPDGFDR2 primer 5Ј-GCTCAGGAAACAAACTCGC-3Ј. The expected PCR products for primer sets 1 and 2 were 360 and 390 bp, respectively, and confirmed by sequencing.
Cell proliferation assay
SMCs were seeded into 96-well plates, and after 48 hours, incubated in serum-free media for 24 hours to induce growth arrest. The cells were exposed to H 2 O 2 in medium containing 0.5% FBS in the presence and absence of goat PDGF-D IgG (Santa Cruz Biotechnology) or goat IgG (2 g/200 L/well; Santa Cruz Biotechnology). After 3 days, the cells were detached with trypsin-EDTA and counted in an automated Coulter Z1 counter.
Results
Isolation of the PDGF-D promoter and identification the transcriptional start site by primer extension analysis
Since the identification of PDGF-D 5 years ago, 7,8 its promoter has not been functionally characterized in any cell type. For this purpose, approximately 1.3 kb of human PDGF-D sequence (Ϫ1168/ϩ185 of GenBank sequence AF336376) was amplified from a human genomic DNA library by PCR. The nucleotide sequence immediately upstream of the predicted transcriptional start site is GϩC rich and lacks a typical TATA box. To determine the authentic transcription start site in the PDGFD gene, we performed primer extension analysis using total RNA extracted from primary SMCs and 2 sets of primers ( Figure 1A ). We observed a single 40-bp extension product using primer B ( Figure  1B) , which maps the start site to CCAGCGC, located 109 bp upstream of ATG, suggesting an unusually short 5Ј untranslated sequence when compared to the PDGFA and PDGFB genes. 18 This transcriptional start site is consistent with the initiator consensus Py Py A ϩ1 N T/A Py Py (where Py denotes pyrimidine) 19 where RNA synthesis usually begins at the adenosine. The 5Ј-flanking region was searched for known transcriptional factor-binding elements using MatInspector 2.0 software. 20 This analysis revealed potential sites for Sp1, AP1, and p53 and no less than 17 separate potential Ets-binding motifs (5Ј-GGAA-3Ј/5Ј-GGAT-3Ј or 5Ј-TTCC-3Ј/5Ј-ATCC-3Ј; Figure 1A ).
Ets-1 activates PDGF-D transcription and mRNA expression in vascular SMCs
The large number of putative Ets-binding sites in the PDGF-D promoter led us to investigate whether Ets-1 could regulate Figure 1A. (B) EMSA (left and top right panels) was performed by incubating 32 P-OligoEts-D3 Ϫ481/Ϫ457 bearing wild-type or mutant Ets element D3 and nuclear extracts of SMCs. A 10 ϫ and 50 ϫ molar excess of unlabeled Oligo Ets-D3 Ϫ481/Ϫ457 wild-type or mutant type Oligo Ets-D3 Ϫ481/Ϫ457 was used in competition analysis. Polyclonal antibodies to Sp1, Ets-1, or p53 (0.5 g) were incubated for 15 minutes prior to the addition of probe. SNC denotes specific nucleoprotein complex. ChIP analysis (right panels) was performed using 2 separate primer sets with antibodies to Ets-1 or Sp1 or no antibody. Antibodies to Ets-1 and Sp1 pulled down the PDGF-D promoter, which was then amplified to produce amplicons of 360 and 390 bp, respectively. The omission of an antibody did not support amplification of any product. NE indicates nuclear extracts. (C) Ets element D3 binds recombinant Ets-1 and Sp1. EMSA was performed with 32 P-OligoEts-D3 Ϫ481/Ϫ457 32 P-OligoEts-D3 Ϫ481/Ϫ457 containing mutant Ets-D3 or Ets-D3-2 and recombinant Ets-1 (100 ng) or Sp1 (100 ng). Free probe was run off the gel. The data are representative of at least 2 independent experiments. Error bars represent SEM performed in duplicate or triplicate. *P Ͻ .05 relative to control using Student t test.
Ets-1 MEDIATES H 2 O 2 -INDUCIBLE PDGF-D TRANSCRIPTION 2325
BLOOD, 15 MARCH 2006 ⅐ VOLUME 107, NUMBER 6 For personal use only. on July 8, 2017. by guest www.bloodjournal.org From PDGF-D expression. SMCs were transfected with the CMV-based Ets-1 expression vector pcDNA3-Ets-1 or its backbone pcDNA3, and PDGF-D mRNA levels were assessed by semiquantitative RT-PCR and real-time PCR after 24 hours. Ets-1 increased PDGF-D expression as compared with the control plasmid, whereas levels of GAPDH remained unaltered (Figure 2A) . We next performed transient cotransfection analysis in SMCs with plasmid p1168PDGF-Dluc, which was created by cloning the Ϫ1168/ϩ185 PDGF-D promoter fragment into the promoterless reporter vector pGL3-basic upstream of Firefly luciferase cDNA, together with pcDNA3-Ets-1 or pcDNA3. Ets-1 activated PDGF-D promoterdependent expression within 24 hours ( Figure 2B ). In contrast, CMV-based expression vectors for other Ets family members such as Fli-1 or PU.1 had no effect on the activity of the PDGF-D promoter (data not shown).
To further demonstrate the positive regulatory influence of Ets-1 on the PDGF-D promoter, we transfected the reporter vector with a plasmid generating a dominant-negative form of Ets-1 (DN-Ets-1), containing only the DNA-binding domain of Ets-1 and lacking the transactivation domain or its backbone pKCR3. This mutant form of Ets-1 failed to stimulate the PDGF-D promoter ( Figure 2C ). Instead, it repressed constitutive promoter-dependent reporter activity ( Figure 2C ), complementing our wild-type overexpression studies and suggesting that Ets-1 is required for basal PDGF-D expression.
Ets site D3 mediates basal activity of the PDGF-D promoter
To identify functional cis-acting elements for Ets-1 in the PDGF-D promoter, we introduced mutations in 4 Ets motifs in p1168PDGF-Dluc, by changing 5Ј-GGAA-3Ј and 5Ј-GGAT-3Ј motifs to 5Ј-TTCC-3Ј and 5Ј-TTCG-3Ј, respectively. Ets-1, as expected, stimulated luciferase activity generated by p1168PDGF-Dluc after 24 hours ( Figure 3A) . It also stimulated the same-fold increase in activity from each mutant plasmid, except mutant D3 ( Figure 3A) , indicating that mutation of the Ϫ470 GGAT Ϫ467 motif abrogates transactivation by Ets-1 ( Figure 3A) . To determine whether Ets-1 physically interacts with element D3, a 32 P-labeled double-stranded oligonucleotide ( 32 P-Oligo Ets-D3 Ϫ481/Ϫ457 ) of 25 bp length spanning this element was used in electrophoretic mobility shift analysis (EMSA) with nuclear extracts from SMCs. This resulted in the formation of several nucleoprotein complexes that were abrogated by a 10-or 50-fold molar excess of unlabeled probe but not by the same fold excess of the unlabeled mutant probe ( Figure  3B ). Of all these complexes, however, the complex of slowest mobility was completely abolished when Ϫ470 GGAT Ϫ467 motif was mutated ( 32 P-Oligo Ets-mD3 Ϫ481/Ϫ457 ; Figure 3B ). This specific nucleoprotein complex (SNC) was eliminated by the presence of polyclonal anti-Ets-1 antibodies, and interestingly, also by antibodies to the zinc finger transcription factor Sp1, but not by antibodies to p53 (Figure 3B ), thus suggesting co-occupancy of this region of the PDGF-D promoter by Ets-1 and Sp1. ChIP analysis using 2 independent primer sets provided compelling evidence that Ets-1 and Sp1 co-occupy this region in the authentic promoter ( Figure 3B ).
To extend these observations, we performed EMSA using 32 P-Oligo Ets-D3 Ϫ481/Ϫ457 with recombinant Sp1 and with Ets-1 bearing only the DNA-binding domain. Both proteins bound to this probe but failed to bind Oligo Ets-mD3 Ϫ481/Ϫ457 ( Figure 3C ). In contrast, 32 P-Oligo Ets-mD3-2 Ϫ481/Ϫ457 bearing a mutation outside the Ϫ470 GGAT Ϫ467 motif still bound each protein ( Figure 3C ).
Sp1 induces PDGF-D expression
To determine whether Sp1 influences PDGF-D expression, we transfected SMCs with the Sp1 expression vector CMV-Sp1, or its backbone CMV-gutless, and assessed PDGF-D mRNA levels by RT-PCR or real-time PCR. Sp1 activated PDGF-D expression within 24 hours ( Figure 4A ). Cotransfection of CMV-Sp1 with p1168PDGF-Dluc increased luciferase reporter activity ( Figure  4B ), whereas cotransfection of a plasmid generating a dominantnegative form of Sp1 (pEBG-DN-Sp1) failed to stimulate the PDGF-D promoter and even repressed constitutive promoterdependent reporter activity ( Figure 4C ). These data demonstrate that Sp1 regulates basal and inducible PDGF-D expression. The capacity of Sp1 to induce PDGF-D transcription extends the regulatory role played by this factor in its control of PDGF-A 21 and PDGF-B 22 expression.
Sp1 activation of PDGF-D transcription is dependent on Ets-1
Because Ets-1 and Sp1 each activate the PDGF-D promoter, and a single element in the PDGF-D promoter supports the interaction of both factors, we performed cotransfection experiments to determine whether activation by one factor requires the other. CMVSp1, as expected, activated PDGF-D promoter-dependent luciferase activity within 24 hours ( Figure 5A ). However, Sp1 stimulation of PDGF-D promoter activity was greatly compromised by the presence of DN-Ets-1 ( Figure 5A ). Additional cotransfection experiments revealed that dual activation of the PDGF-D promoter by Ets-1 and Sp1 was additive and not synergistic ( Figure 5B ). That Sp1 was still able to transactivate p1168PDGF-Dluc bearing (1-3 g) or the corresponding amount of CMV-gutless together with 10 g p1168PDGF-Dluc to demonstrate Sp1 dependence. Promoter activity was assessed after 24 hours. Results are expressed as fold induction compared with backbone vector. (C) SMCs were cotransfected with 3 g of Sp1 plasmid or dominant-negative Sp1 (pEBG-DN-Sp1), respectively, together with 10 g p1168PDGF-Dluc. Luciferase activity was determined after 24 hours. The data are representative of at least 2 independent experiments. Error bars represent SEM performed in duplicate or triplicate. *P Ͻ .05 relative to control using Student t test. a mutation in D3 ( Figure 5B ) indicates that Sp1, unlike Ets-1 ( Figure 3A) , can use promoter elements other than D3 to drive PDGF-D transcription.
Ets-1 mediates H 2 O 2 stimulation of PDGF-D expression
To demonstrate the pathophysiologic relevance of these findings, we treated growth-quiescent SMCs with 10 nM (Figure 6C) . Similar effects were observed with cells transfected with p1168PDGF-Dluc bearing mutant site D4 ( Figure 6C ). H 2 O 2 , however, failed to induce the PDGF-D promoter containing mutant D3 ( Figure 6C ). To demonstrate the critical role played by endogenous Ets-1 in H 2 O 2 modulation of PDGF-D expression, we used siRNA 23 to silence Ets-1. Ets-1 siRNA blocked the induction of both Ets-1 and PDGF-D mRNA in response to H 2 O 2 ( Figure  6D ). Sp1 siRNA also blocked H 2 O 2 -inducible PDGF-D expression ( Figure 6D) , whereas an irrelevant size-matched siRNA had no effect at the same concentration ( Figure 6D ). Real-time PCR analysis further demonstrated the Ets-1 and Sp1 dependence of inducible PDGF-D mRNA expression ( Figure 6E ). That Sp1 siRNA inhibited Ets-1 expression as well as itself is consistent with the existence of at least 5 Sp1 sites in the Ets-1 promoter. 24, 25 Autocrine/paracrine growth involving PDGF-D
We next performed proliferation experiments in which primary SMCs were exposed to H 2 O 2 in the absence or presence of goat polyclonal PDGF-D antibodies or goat IgG. A 2-fold increase in (F) SMCs were exposed to H2O2 (100 nM) in the absence or presence of goat polyclonal PDGF-D antibodies or goat IgG and total cell counts were determined after 3 days using a Coulter counter. Alternatively the cells were exposed to 5% serum for control purposes. The data are representative of at least 2 independent experiments. Error bars represent SEM performed in duplicate or triplicate. *P Ͻ .05 relative to control using Student t test. For personal use only. on July 8, 2017 . by guest www.bloodjournal.org From SMC counts was observed after 3 days of incubation with H 2 O 2 ( Figure  6F ). The mitogenic effect of H 2 O 2 was abrogated by the presence of PDGF-D antibodies, whereas identical amounts of IgG had only a comparatively modest effect ( Figure 6F ). These findings suggest that an autocrine/paracrine growth stimulatory loop involving PDGF-DD mediates H 2 O 2 -inducible SMC proliferation, because PDGF-D does not appear to heterodimerize with other PDGF chains.
ATII is known to stimulate the production of reactive oxygen species from NAD(P)H oxidase in SMCs. 26 27 Catalase has been used to block the ATII-inducible expression of pathophysiologically relevant genes such as monocyte chemoattractant protein-1 in SMCs. 28 ATII (10 Ϫ7 M) activated PDGF-D mRNA ( Figure 7A ) and protein (50 and 21 kDa forms; Figure 7B ) expression in SMCs. Moreover, ATII induction of PDGF-D and Ets-1 were blocked by prior incubation of the cells with PEG-catalase ( Figure 7C-D 
Discussion
Here we have functionally characterized the PDGF-D promoter. Primer extension analysis mapped the transcriptional start site to the CCAGCGC motif. Ets-1, but not a dominant-negative form of Ets-1, activates PDGF-D promoter-dependent reporter gene expression and endogenous PDGF-D mRNA expression. Mutational analysis demonstrated that D3 ( Ϫ470 GGAT Ϫ467 ) mediates both basal and Ets-1-inducible PDGF-D promoter-dependent expression. Binding analysis revealed that this site supports the interaction of endogenous Ets-1 and Sp1. H 2 O 2 stimulates both Ets-1 and PDGF-D expression but has no effect on Sp1. PDGF-D transcription inducible by peroxide is critically dependent on the integrity of D3 and the presence of both Ets-1 and Sp1. Thus, the PDGF-D promoter is eminently regulated by Ets-1 and Sp1, alone and together, via D3, and responds positively to hydrogen peroxide through this element.
Oxidative stress induced as a consequence of excess reactive oxygen species may cause vascular dysfunction and subsequent cardiovascular disease via its effects on cell proliferation, differentiation, and cell death. Under conditions of oxidative stress, redox-sensitive transcription factor activation underpins the inducible expression of key genes altering vascular phenotype. Growth factors such as PDGF-A, PDGF-B, VEGF, and fibroblast growth factor are examples of genes regulated by oxidative stress. We have shown here that PDGF-D is regulated by H 2 O 2 via Ets-1 and element D3. Moreover, our catalase blockade experiments demonstrate that ATII-inducible Ets-1 and PDGF-D expression is mediated via H 2 O 2 . These studies, performed in SMCs, have implications to other cell types. For example, Yasuda and colleagues reported that H 2 O 2 -inducible endothelial cell tubule formation and proliferation are processes mediated by increased levels of Ets-1 29 although in their study, actual Ets-1-dependent genes mediating H 2 O 2 -inducible angiogenesis were not identified. PDGF-D, which plays a permissive role in angiogenesis 9 is, based on the present study, one such candidate. Although the broader biologic functions of PDGF-D have not been fully characterized, identification of key transcriptional modulators of its expression, such as Ets-1 and Sp1, will help us better understand its physiologic and pathophysiologic role and provide future opportunities for molecular intervention and inhibition. The data are representative of at least 2 independent experiments. Error bars represent SEM performed in duplicate or triplicate. *P Ͻ .05 relative to control using Student t test.
